Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
featured
Published in Metastatic Breast Cancer

Expert Opinion / Cases · July 13, 2021

T3N2 ER-PR- HER2+ Invasive Ductal Carcinoma of the Left Breast

Ana Sandoval Leon MD

 

 Save  Recommend
 Share

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • oscar aballay

    Jul 14, 2021

    4

  • Swapan Kumar   Nath

    Jul 14, 2021

    I suggest trastuzumab deruxtecan

  • EMADMOHSEN EL-NASHAR

    Jul 16, 2021

    4

  • Zuhair ALZIBAIR

    Jul 16, 2021

    There was a partial response to docetaxel PH initially ...since the goal of the treatment is palliative in principle ,I suggest re-challenge with weekly paclitaxel- trastuzumab pertuzumab

  • Gail Morris

    Jul 16, 2021

    5 Start with SBRT to liver, then 4, if the patient agrees.  I’m speaking as a physician with ER-PR-HER2+ ductal carcinoma with no recurrence of liver mets after 14 years.  The word “palliative” is not in my vocabulary.  I never comment on forums but feel like I need to weigh in on this one.  If even one oncologist reading this considers SBRT in a case such as this, I will be happy.

  • Kavi Capildeo

    Jul 17, 2021

    3 or 4

  • Barb Stein

    Jul 17, 2021

    As a RN with Er Pr neg HER2+ with mets to my liver. SBRT to liver mets after 6 rounds of THP followed by H&P (Cleopatra trial). Did the trick for me! 6 years NED on H&P.

  • Barb Stein

    Jul 18, 2021

    As she had a reoccurrence 3 years out, first line metastatic would be 1 and since oligometastisis SBRT to any residual met.

  • surapong  supaporn

    Jul 18, 2021

    Ans. 1
: as cleopatra trial 
: recurrent after 3 years completion of adjuvant therapy 
:

  • Rham Zaki

    Oct 10, 2021

    Rechallange ,,answer no.1

  • Jan 22, 2025

    Pending Moderator approval.
    Delete

Further Reading

Most Read This Week

Recently Updated